News

Kolltan has also appointed Michael Schmertzler as its new CEO and director, and Yaron Hadari as vice president of research. Joseph Schlessinger, co-founder, chief scientist and a director

The milestone payment is triggered by the recent FDA approval of Prism’s new drug application (NDA) for Nexterone (amiodarone HCl) injection, a patent-protected, cosolvent free formulation of the

Mr Buehler is currently senior vice president of global markets and chief marketing officer of Alcon Laboratories, a subsidiary of Alcon. In this capacity, he is responsible for

Midwest Dental is a dental management company headquartered in Mondovi, Wisconsin. Under the terms of this multi-year agreement, OralDNA will provide diagnostic laboratory testing to Midwest Dental to

According to Synosia Therapeutics, the proceeds will be used to fund the ongoing development of its emerging portfolio of Phase II clinical programs. The financing was led by

In preclinical models, the calcium release-activated calcium modulator inhibitors discovered by Synta potently and selectively inhibited the secretion of pro-inflammatory factors such as TNF-alpha and IL-2, with minimal

The company is currently enrolling patients in three separate protocols: two are randomized, controlled studies of patients with ACLF (acute-on-chronic liver failure) or FHF (fulminant hepatic failure). Continuous

Advaxis has submitted its investigational new drug (IND) application to the FDA in May 2008, which outlined the proposed protocol for a Phase II clinical trial safety study

AM211 is an oral, selective antagonist of the receptor DP2 (also known as CRTH2 or chemoattractant receptor-homologous molecule expressed on Th2 lymphocytes). DP2 is a high affinity receptor